Calcipotriol/Betamethasone Dipropionate (Enstilar)
Is It Right for You?
A complete guide to Calcipotriol/Betamethasone Dipropionate (Enstilar) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Calcipotriol/Betamethasone Dipropionate (Enstilar)?
Enstilar is a cutaneous foam formulation containing two complementary anti-psoriatic agents: calcipotriol 50 micrograms/g (a synthetic vitamin D3 analogue) and betamethasone dipropionate 0.5 mg/g (a potent synthetic corticosteroid). It is licensed for the topical treatment of mild to moderate plaque psoriasis vulgaris of the body and scalp in adults.
The foam vehicle provides several clinical advantages over gel and ointment formulations of the same combination: superior spreading and penetration, cosmetic acceptability, ease of application to the scalp and body, and rapid drying without greasy residue. Clinical studies demonstrate that Enstilar foam achieves superior disease control outcomes at four weeks compared to equivalent gel formulations, attributable to enhanced drug penetration through the foam vehicle.
Enstilar is a prescription-only medication in the UK. A licensed clinician must assess the extent and severity of psoriasis, risk of systemic corticosteroid absorption, and contraindications before prescribing.
What Conditions Is Enstilar Used For?
Plaque psoriasis vulgaris (mild to moderate, body and scalp) — reduction of scaling, thickening, and erythema of psoriatic plaques.
Certain bacterial skin infections caused by susceptible organisms.
(mild to moderate, body and scalp) — reduction of scaling, thickening, and erythema of psoriatic plaques
Psoriasis is a chronic, immune-mediated inflammatory disease. Enstilar effectively reduces active plaque disease and can induce clearance or near-clearance of treated lesions, but it does not address the immunological basis of the condition. Ongoing management, including regular clinical review and, for moderate to severe disease, consideration of systemic or biological therapies, remains important.
How Does Enstilar Work?
Enstilar combines two agents acting through distinct but complementary mechanisms:
Calcipotriol (vitamin D3 analogue) — calcipotriol binds to vitamin D receptors (VDRs) in keratinocytes and immune cells within the psoriatic plaque. Activation of VDRs normalises keratinocyte differentiation and proliferation — the pathological hyperproliferation of which produces the characteristic scaling and thickening of psoriatic plaques. Calcipotriol also has anti-inflammatory effects, reducing the release of pro-inflammatory cytokines by T-cells and dendritic cells within the plaque.
Betamethasone dipropionate (potent corticosteroid) — betamethasone binds to intracellular glucocorticoid receptors in skin cells, exerting potent anti-inflammatory effects by inhibiting phospholipase A2 (reducing arachidonic acid availability for prostaglandin and leukotriene synthesis), suppressing pro-inflammatory cytokine gene expression, and reducing capillary permeability and vasodilation within the plaque. This produces rapid reduction in erythema, oedema, and pruritus.
The combination of calcipotriol's antiproliferative/immunomodulatory action with betamethasone's potent anti-inflammatory action results in additive and complementary disease control that is superior to either component used alone.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Shake the can well before each use. Hold the can upside down and apply the foam directly onto the affected skin or into the hand before applying.
Apply to lesion surfaces only — avoid application to uninvolved skin; this minimises corticosteroid-related skin thinning in unaffected areas.
Do not use under occlusion (e.g. wrapped in cling film or under tight bandages) unless specifically directed by your clinician; occlusion markedly increases corticosteroid absorption.
Avoid the face, armpits, and groin — these are areas of thin skin and skin folds where corticosteroid absorption is enhanced and adverse effects more likely. Specialised treatments are available for facial or flexural psoriasis.
Wash hands after application unless the hands are a treatment area.
Maximum dose of 15 g per day and 100 g per week — exceeding recommended quantities significantly increases the risk of systemic corticosteroid effects and hypercalcaemia from calcipotriol
Side Effects of Enstilar
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Local skin irritation, pruritus, or burning at the application site
- Folliculitis (inflammation of hair follicles within treated areas)
- Dry skin
- Skin atrophy and striae — prolonged or excessive corticosteroid use causes thinning of the skin, stretch marks, and telangiectasia; most likely in areas of thin or occluded skin
- Adrenal suppression — systemic absorption of betamethasone with high-dose or prolonged use can suppress the hypothalamic-pituitary-adrenal (HPA) axis
- Hypercalcaemia — excessive use of calcipotriol can elevate serum calcium; nausea, weakness, polyuria, confusion; risk with doses exceeding 100 g/week
- Rebound psoriasis — abrupt discontinuation of potent corticosteroids can precipitate a rebound flare or, in rare cases, conversion to pustular psoriasis
- Perioral dermatitis / rosacea-like reactions — particularly if inadvertently applied to the face
Betamethasone dipropionate is a potent (class III) corticosteroid. Excessive or prolonged use — particularly on large body surface areas, under occlusion, or on thin skin — can result in clinically significant systemic absorption with HPA axis suppression, Cushingoid features, and iatrogenic adrenal insufficiency. Strict adherence to maximum doses and treatment duration limits is essential.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Enstilar
concurrent use of calcipotriol with oral vitamin D supplements or calcium supplementation increases the risk of hypercalcaemia; monitor serum calcium with high doses.
Increase risk of hypercalcaemia when combined with calcipotriol; monitor calcium levels.
apply Enstilar separately from moisturisers and other topical agents; allow one agent to absorb fully before applying another.
Important Warnings
Do not exceed 15 g per day or 100 g per week. Exceeding these quantities risks HPA axis suppression from betamethasone and hypercalcaemia from calcipotriol. In routine clinical use, treatment should not extend beyond four consecutive weeks without clinical review.
Potent topical corticosteroids should not be stopped abruptly after prolonged use. Gradual dose reduction or switching to a maintenance regimen is recommended to reduce the risk of a severe rebound psoriasis flare.
Enstilar is not indicated for the face, genital area, or skin folds, where corticosteroid absorption is substantially enhanced and adverse effects — including skin atrophy, striae, and rosacea-like reactions — are more likely to occur.
Potent topical corticosteroids are not recommended for extensive use during pregnancy. Calcipotriol should be avoided on the breasts if breastfeeding.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Enstilar FAQs
The foam vehicle provides superior penetration of active ingredients through the skin compared to equivalent gel or ointment formulations, resulting in better efficacy. It is also cosmetically more acceptable — it absorbs quickly, leaves no greasy residue, and is easy to apply to the scalp and larger body areas.
Yes — Enstilar is specifically licensed for scalp psoriasis and is an excellent choice for this location given its foam vehicle and easy application to hair-bearing skin. Part the hair before applying and massage gently into affected areas.
Many patients notice a reduction in itch and redness within the first one to two weeks. Significant plaque clearance typically occurs within four weeks of once-daily use.
No. Enstilar is approved for up to four weeks of daily treatment, after which the response should be assessed. For maintenance, some patients use Enstilar twice weekly under clinical supervision. Indefinite daily use risks progressive skin thinning, HPA axis suppression, and hypercalcaemia.
Do not stop abruptly after extended use. Your clinician will advise a step-down approach — often switching to twice-weekly use for a maintenance period — to reduce the risk of a rebound flare.